Quantcast

Efficacy and safety of hepatitis C antiviral therapy in moderate and severe chronic kidney disease.

Research paper by Jeyamani J Ramachandran, Ramit R Mahajan, Gopal G Basu, P L PL Alagammai, Jayashree J Sivakumar, Ashish A Goel, Priya P Abraham, V V Tamilarasi

Indexed on: 13 Jul '14Published on: 13 Jul '14Published in: Indian Journal of Gastroenterology



Abstract

Hepatitis C virus (HCV) infection is an important cause of liver-related morbidity and mortality in patients with end-stage renal disease (ESRD). Though indicated, antiviral therapy adds to the existing financial burden and is poorly tolerated in these patients. We studied HCV treatment outcomes in patients with moderate and severe chronic kidney disease (CKD) between June 2010 and June 2012. Out of 46 patients with CKD, only 16 (genotype 1:6, 3:9, indeterminate 1) received interferon treatment (conventional 9, pegylated 7; with low-dose ribavirin 5). End of treatment response was achieved in 50 % and sustained viral response in 44 %. Adverse effects such as tuberculosis, anemia, and cardiac failure resulting in discontinuation of therapy were seen in three. The dropout rate was 38 %. Though interferon therapy was efficacious and safe, it was received by only 35 % of patients with CKD. We suggest that antiviral therapy be offered under close monitoring in the absence of contraindications in patients with moderate and severe CKD.